Original Article

Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer

  1. Zumre A. Alicikus MD1,
  2. Yoshiya Yamada MD1,
  3. Zhigang Zhang PhD2,
  4. Xin Pei PhD1,
  5. Margie Hunt MA3,
  6. Marisa Kollmeier MD1,
  7. Brett Cox MD1,
  8. Michael J. Zelefsky MD1,†,*

Article first published online: 8 NOV 2010

DOI: 10.1002/cncr.25467

Issue

Cancer

Cancer

Volume 117, Issue 7, pages 1429–1437, 1 April 2011

Additional Information

How to Cite

Alicikus, Z. A., Yamada, Y., Zhang, Z., Pei, X., Hunt, M., Kollmeier, M., Cox, B. and Zelefsky, M. J. (2011), Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer, 117: 1429–1437. doi: 10.1002/cncr.25467

Author Information

  1. 1

    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York

  3. 3

    Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York

  1. †

    Fax: (212) 639-8876

*Department of Radiation Oncology, 1275 York Avenue, New York, NY 10065

Publication History

  1. Issue published online: 18 MAR 2011
  2. Article first published online: 8 NOV 2010
  3. Manuscript Accepted: 4 JAN 2010
  4. Manuscript Revised: 24 DEC 2009
  5. Manuscript Received: 4 SEP 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (391K)

Keywords:

  • high-dose;
  • intensity-modulated radiotherapy;
  • prostate cancer;
  • prostate-specific antigen

The authors investigated long-term tumor-control and toxicity outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in patients with clinically localized prostate cancer. High-dose IMRT was well tolerated and was associated with excellent long-term tumor-control outcomes in these patients.

Abstract

BACKGROUND.

The authors investigated long-term tumor control and toxicity outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in patients who had clinically localized prostate cancer.

METHODS.

Between April 1996 and January 1998, 170 patients received 81 gray (Gy) using a 5-field IMRT technique. Patients were classified according to the National Comprehensive Cancer Network-defined risk groups. Toxicity data were scored according to the Common Terminology Criteria for Adverse Events Version 3.0. Freedom from biochemical relapse, distant metastases, and cause-specific survival outcomes were calculated. The median follow-up was 99 months.

RESULTS.

The 10-year actuarial prostate-specific antigen relapse-free survival rates were 81% for the low-risk group, 78% for the intermediate-risk group, and 62% for the high-risk group; the 10-year distant metastases–free rates were 100%, 94%, and 90%, respectively; and the 10-year cause-specific mortality rates were 0%, 3%, and 14%, respectively. The 10-year likelihood of developing grade 2 and 3 late genitourinary toxicity was 11% and 5%, respectively; and the 10-year likelihood of developing grade 2 and 3 late gastrointestinal toxicity was 2% and 1%, respectively. No grade 4 toxicities were observed.

CONCLUSIONS.

To the authors' knowledge, this report represents the longest followed cohort of patients who received high-dose radiation levels of 81 Gy using IMRT for localized prostate cancer. The findings indicated that high-dose IMRT is well tolerated and is associated with excellent long-term tumor-control outcomes in patients with localized prostate cancer Cancer 2011. © 2010 American Cancer Society.

View Full Article (HTML) Get PDF (391K)